Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
The trial investigates the use of CLN-978, a CD19-directed T cell engager given by subcutaneous injection, for treating adults with moderate to severe Systemic Lupus Erythematosus SLE. This Phase 1b open-label study focuses on evaluating the safety and tolerability of the treatment in patients who have active disease despite prior therapies. The research aims to explore how the drug interacts with the body and its effects on immune biomarkers over 48 weeks. Participants receive CLN-978 through specified doses on certain days, starting with dose escalation cohorts followed by further dose evaluations. The study is non-randomized and open-label, meaning all participants receive the study drug. Treatment is administered subcutaneously, and the study includes two parts Part A focuses on dose escalation and Part B on additional dose evaluation for those who tolerate initial treatment. During the trial, participants undergo regular safety assessments, laboratory tests, and biomarker monitoring for up to 48 weeks. Researchers measure how well patients tolerate the drug, its pharmacokinetics, immunogenicity, and related pharmacodynamic biomarkers. The study lasts until late 2027, with ongoing evaluations to understand the treatments impact on SLE disease activity and patients health.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Afimkibart also known as RO7790121 in adults with moderate to severe rheumatoid arthritis RA who have not responded well or cannot tolerate tumor necrosis factor TNF andor Janus kinase JAK inhibitors. This Phase II, multicenter, randomized, double-blind, placebo-controlled study aims to compare Afimkibart with placebo in this group to better understand its impact on disease activity. Participants will receive either Afimkibart or a placebo through subcutaneous under the skin injections. The study includes two experimental groups receiving Afimkibart and one placebo group, all administered by injection. Treatment and assessments occur over several weeks, with key evaluations at Week 14 and Week 24 to measure changes in disease activity and response. During the study, participants will undergo various assessments including joint counts, patient and physician global assessments, laboratory tests for inflammation markers, and questionnaires on health status and pain. The main outcome is the change in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein DAS28-CRP at Week 14. Safety will be monitored throughout the trial up to Week 38, including tracking adverse events and immune responses to the drug. Participants can expect regular visits for injections and evaluations during this period.
Actively Recruiting
Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.
Actively Recruiting
Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.
Actively Recruiting
Researchers are evaluating two experimental drugs, REGN7508 and REGN9933, in adults with Peripheral Artery Disease PAD, a condition where blood vessels in the arms and legs become narrowed. This study aims to compare these drugs to rivaroxaban and a placebo in preventing serious blood clots after Lower Extremity Revascularization LER, a procedure to improve blood flow. The trial also investigates the side effects of these drugs, their blood levels, immune responses to the drugs, and effects on blood clotting. Participants will be randomly assigned to receive REGN7508, REGN9933, rivaroxaban, or a placebo, all given according to the study protocol. The study will follow participants for up to about 42 months to observe the occurrence of major thrombotic events such as acute limb ischemia, major amputations, heart attacks, strokes, or cardiovascular death. Additional monitoring of bleeding events and immune responses to the drugs will continue for up to approximately 45 months. During the study, participants will have regular assessments including blood tests to measure drug levels and clotting function, and evaluations for any bleeding or clotting events. Researchers will track safety by monitoring adverse events and the bodys immune response to the study drugs. The long follow-up period allows detailed observation of the treatments effects and safety over time. Participants are followed until the study completion or withdrawal.
Actively Recruiting
Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the VDI UHF-ECG System for diagnosing ventricular dyssynchrony in patients with bradycardia and heart failure who are scheduled for pacemaker implantation. This observational study compares the new Ultra High Frequency Electrocardiogram UHF-ECG device with the standard 12-lead ECG to see how well it predicts electrical dyssynchrony in the heart. Participants will undergo both the standard ECG and the UHF-ECG measurements sequentially before their pacemaker procedure. The study focuses on adults with specific heart conditions such as bradycardia with different conduction patterns or heart failure with left bundle branch block. The investigational device is used to gather detailed electrical activity data to improve diagnosis. During the study, researchers will collect and compare ECG data from both devices before the pacemaker implant. Participants will be monitored for predictive agreement between the UHF-ECG and standard ECG results. The study involves informed consent, adherence to study procedures, and a pregnancy test for women of childbearing potential. The trial is expected to continue until May 2027.